VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

N. meningitidis TbpA Protein Vaccine
Vaccine Information
  • Vaccine Name: N. meningitidis TbpA Protein Vaccine
  • Target Pathogen: Neisseria meningitidis
  • Target Disease: Meningitis
  • Vaccine Ontology ID: VO_0004064
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: rTbpA
  • tbpA gene engineering:
    • Type: Recombinant protein preparation
    • Description:
    • Detailed Gene Information: Click Here.
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0000139
    • Description: Vaccines were prepared with an equal volume of either Freund's complete adjuvant (first immunization) or Freund's incomplete adjuvant (subsequent immunizations) (West et al., 2001).
  • Adjuvant:
    • Adjuvant name:
    • VO adjuvant ID: VO_0000142
    • Description: Vaccines were prepared with an equal volume of either Freund's complete adjuvant (first immunization) or Freund's incomplete adjuvant (subsequent immunizations) (West et al., 2001).
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Host Strain: NIH
  • Vaccination Protocol: Each mouse received 0.2 ml, containing 10 μg of rTbpA protein and Freund's complete adjuvant, by subcutaneous injection. All animals were immunized on days 1, 21, and 28 (West et al., 2001).
  • Challenge Protocol: Mice were infected by intraperitoneal injection of N. meningitidis at several challenge doses (West et al., 2001).
  • Efficacy: 100% protection was afforded by vaccination with rTbpA at the 2 × 10^7 CFU challenge dose andat the 2 × 10^8 CFU challenge dose, the rTbpA-vaccinated group had an 85% survival rate (West et al., 2001).
References
West et al., 2001: West D, Reddin K, Matheson M, Heath R, Funnell S, Hudson M, Robinson A, Gorringe A. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infection and immunity. 2001; 69(3); 1561-1567. [PubMed: 11179327].